Date
23 January 2018
GSK, J&J, Mylan leading much-needed antibiotic R&D efforts, new index finds
Sarah Owermohles reports for S&P Global Market Intelligence on the companies that are most active in addressing antimicrobial resistance.
The article covers the Antimicrobial Resistance Benchmark, focusing on the key findings on the performance of large research-based pharmaceutical companies, generic medicine manufacturers and biopharmaceutical companies in the scope of analysis and their efforts to curb antimicrobial resistance.